ORIGIN
Brief description of study
Study is enrolling IgAN patients who continue to have persistent proteinuria despite being on RAAS inhibitors for at least 12 weeks. The study intervention is subcutaneous atacicept given once a week. Interested subjects will be taking study drug for up to 96 weeks (36 weeks blinded + 60 weeks open label). Procedures include clinical lab assessments for routine labs, ECG, vitals, Physical exam, and study questionnaires.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
